Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Phonophoresis group, ultrasound only and Therapeutic exercises.
- Who it may be relevant to
- Registry conditions: Planter Fasciitis. Basic parameters: 18 years — 44 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Glyceryl Trinitrate Gel Phonophoresis in Treatment of Plantar Fasciitis: A Randomized Controlled Trial
Overview
Does phonophoresis with glyceryl trinitrate gel have an effect in treatment of planter fasciitis patients?
Detailed description
Plantar fasciitis (PF), considered the most common cause of sub-calcaneal pain, was first described in 1812, related to painful sensation in the calcaneus, resulting from degeneration of the plantar fascia. Some reported cases are the result of biomechanical failure that provides tension along the plantar fascia. It is a common dysfunction in runners, due to the high loads they exert on the plantar fascia, but other risk factors are also worth mentioning, such as increased planter flexion, high body mass and high body mass index phonophoresis emerges as a valuable and versatile modality within physiotherapy, demonstrating clinical efficacy across a spectrum of musculoskeletal and inflammatory conditions. The combination of topically applied gel or cream-based medications with ultrasound therapy, operating within specific frequency and intensity ranges, enhances percutaneous absorption of pharmacological agents.
Glyceryl trinitrate can directly relax vascular smooth muscles, especially the smooth muscle of small blood vessels, thus dilating blood vessels and improving the microcirculation. In addition, nitroglycerin interacts with intracellular sulfhydryl to release nitric oxide (NO). NO, as endothelial relaxing factor, activates guanylate cyclase to transform into cyclic guanosine monophosphate (cGMP), which increases cGMP in smooth muscles and other tissues, thereby causing dephosphorylation of myosin light chain, regulating the contractile state of smooth muscles, relaxing smooth muscles, and dilating blood vessels gap in literature about the effect of glyceryl trinitrate gel in treatment of plantar fasciitis. So the aim of this study is to investigate the effect of glyceryl trinitrate gel in treatment of plantar fasciitis.
Interventions
- Other Phonophoresis group
1. Patients will receive Phonophoresis with topical glyceryl trinitrate gel. Using pulsed ultrasound (2:1) with the frequency of 0.8 MHz and intensity of 1.5 W/CM for 10 minutes was dynamically administered for the patients in 10 every other day sessions. 2. Therapeutic exercises * Tibialis anterior strengthening (four sets of ten repetitions, with weights of 3 to 5 kg) * Plantar fascia stretching the patient was comfortably sitting on chair with tennis ball under his foot. Then he rolls - Other ultrasound only and Therapeutic exercises
1. Patients will receive ultrasound at a frequency of 1.0 Hz and intensity of 1.2 watts/cm². Ten sessions were undertaken at a frequency of two sessions per week. 2. therapeutic exercises.
Primary outcome measures
- Ultrasonography [Time frame: From enrollment to the end of treatment at 5 weeks]
Secondary outcome measures (4)
- visual analogue scale [Time frame: From enrollment to the end of treatment at 5 weeks]
- 6-Minu Walk Test [Time frame: From enrollment to the end of treatment at 5 weeks]
- Smartphone apps [Time frame: From enrollment to the end of treatment at 5 weeks]
- Arabic version of modified foot function index (FFI) [Time frame: From enrollment to the end of treatment at 5 weeks]
Eligibility criteria
Inclusion criteria
- Age between 18-44 years .
- Patients BMI 18.5 to 24.9 kg / m2.
- The diagnosis of PF appear clinically according to the history and physical - examination findings of point tenderness at or near the medial calcaneal insertion of the plantar fascia .
- Diagnosis of plantar fasciitis, with plantar fascia of more than 4 mm thickness as evaluated by ultrasonography.
- Painful symptoms lasting three months or more .
Exclusion criteria
- Diabetes mellitus, peripheral neuropathy, vasculitis and vasculopathy.
- Any pathology in ankle/foot (instability, arthritis, malignancy, acute infection, and skin disorders) .
- Pregnancy or lactation, coronary artery disease, hypertension, renal diseases and anemia .
- Atrophy/ scar or skin ulcers at the site of intervention.
- Patients with allergy to nitrates.
- Heart pacemaker use .
- Anticoagulant use and absence of coagulation disease.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo university — Cairo
Identifiers
NCT: NCT07480876 · P.T.REC/012/005852